Showing results (161-170 of 223) with videos related to
Sort By:
Pageof 23
Cell Communication and Signaling : CCS|April 30, 2025
Endoplasmic reticulum stress disrupts signaling via altered processing of transmembrane receptorsMichaela Bosakova, Sara P Abraham, Davis Wachtell, et al.Journal of Cancer Research and Clinical Oncology|April 11, 2014
Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemiaMarkus Pfirrmann, Susanne Saussele, Andreas Hochhaus, et al.Blood|April 7, 2011
Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-FreseniusGérard Socié, Claudia Schmoor, Wolfgang A Bethge, et al.The Lancet. Oncology|August 22, 2009
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trialJürgen Finke, Wolfgang A Bethge, Claudia Schmoor, et al.Blood Advances|March 6, 2024
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomesMaria Agustina Perusini, Daniela Žáčková, Taehyung Kim, et al.The Lancet. Oncology|February 23, 2016
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trialMarek Trněný, Thierry Lamy, Jan Walewski, et al.The New England Journal of Medicine|May 31, 2024
Asciminib in Newly Diagnosed Chronic Myeloid LeukemiaAndreas Hochhaus, Jianxiang Wang, Dong-Wook Kim, et al.Blood|April 15, 2025
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapyNaval G Daver, Paresh Vyas, Gerwin A Huls, et al.American Journal of Hematology|February 6, 2024
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitorsTomas Hornak, Jiri Mayer, Petra Cicatkova, et al.Haematologica|July 2, 2026
Favorable tolerability of asciminib <i>versus</i> ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemiaGhayas C Issa, Richard A Larson, Timothy P Hughes, et al.Pageof 23